Project Grant R01CA295996
Award Date 8/7/25
Completion Date 7/31/30
Dollars Obligated $659K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tennessee, USA
Similar Awards
- This Project Grant award of $2,840,768 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to enhance the therapeutic efficacy and minimize side effects of the chemotherapy drugs cyclophosphamide (CPA) and doxorubicin (DOX) in treating triple-negative breast cancer (TNBC). The key objectives are to improve the metabolic activation of CPA and mitigate the cardiotoxicity of DOX by leveraging dual activation of the human constitutive androstane receptor (HCAR) and...
- This federal Project Grant award of $590,625.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by the University of California, Davis to develop a novel therapeutic strategy targeting mutant p53 in cancer. The key objectives are to: Determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and evaluate the role of mutant p53 as a target for CDK4/6 inhibitors to suppress triple negative breast cancers (TNBCs)....
- This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Promilead, LLC to activate the TFEB protein and enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The key objectives are to: Determine how TFEB expression and activation in TNBC cells can favorably modulate tumor-associated macrophages to suppress tumor growth. Prior research has shown that TFEB has tumor suppressive roles in breast...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $616,071 to The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop novel adenosine receptor inverse agonists for the treatment of metastatic triple negative breast cancer (TNBC). The project, which runs from February 2025 to January 2030, involves a partnership between UTHSCSA and Riverwalk Therapeutics, Inc., a spin-off company incorporated by UTHSCSA....
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) for the project "Preclinical Efficacy of GPR56 Antibody-Drug Conjugates and Combination Therapies for Triple-Negative Breast Cancer". The 24-month grant aims to develop and evaluate GPR56 antibody-drug conjugates (ADCs) as a novel targeted therapy for triple-negative breast cancer (TNBC),...
- This $781,436 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research by Cold Spring Harbor Laboratory to optimize anti-NMDAR (N-methyl-D-aspartate receptor) antibodies for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) establish an orthotopic mouse model of NMDAR-positive TNBC, 2) screen for anti-NMDAR antibodies that can effectively target NMDAR-positive TNBC cells while...
- This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), is focused on identifying the metabolic dysregulation and signaling pathways governing metastasis in triple-negative breast cancer (TNBC), and developing novel interventions to prevent this deadly disease. The $631,492 award to The University of Kentucky Research Foundation will support research to determine how the enzyme nicotinamide N-methyltransferase (NNMT) promotes...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports research to evaluate the preclinical and clinical activity of DNA methyltransferase (DNMT) inhibitors in combination with chemoimmunotherapy for patients with triple-negative breast cancer (TNBC). The $472,447 award, effective December 1, 2024, focuses on identifying biomarkers, such as DNMT3A expression, that can predict response to these targeted therapies. The proposed...
- This $403,485 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of novel platinum-based therapeutics that can effectively induce high levels of reactive oxygen species (ROS) to treat triple-negative breast cancer (TNBC). The research, conducted by The Methodist Hospital Research Institute in Texas, aims to create new drug candidates that can rapidly eradicate TNBC cells and suppress tumor growth, particularly in cases...